Suppr超能文献

新冠病毒病对慢性阻塞性肺疾病的长期影响

Long-Term Effects of COVID-19 on Chronic Obstructive Pulmonary Disease.

作者信息

Lee Chi-Tai, Wang Ping-Huai, Cheng Shih-Lung

机构信息

Division of Pulmonology, Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan.

Department of Nursing, Asia Eastern University of Science and Technology, New Taipei City, Taiwan.

出版信息

Int J Chron Obstruct Pulmon Dis. 2025 Jul 18;20:2539-2548. doi: 10.2147/COPD.S523149. eCollection 2025.

Abstract

BACKGROUND

Research has demonstrated that chronic obstructive pulmonary disease (COPD) is a negative prognostic factor for patients with the coronavirus disease 2019 (COVID-19). The long-term complications of COVID-19 among patients with COPD remain poorly understood due to limited studies.

METHODS

This retrospective study included patients with COPD who underwent regular follow-ups in a medical center between January 1, 2020, and December 31, 2022. The patients were categorized into COVID-19 and non-COVID-19 groups. Comparative analyses were conducted to assess clinical demographics, characteristics, acute exacerbations of COPD (AECOPD), and survival rates between the two groups. Subgroup analysis was performed based on inpatient and outpatient status within the COVID-19 group.

RESULTS

Of the 696 patients with COPD, 86 (12.4%) were included in the COVID-19 group, while 610 (87.6%) were included in the non-COVID-19 group. Patients in the COVID-19 group were significantly older (age: 75.0 ± 8.8 years versus 72.0 ± 9.0 years, = 0.004), exhibited higher mortality rates (4.6% versus 0%, < 0.001), and increased annual times of AECOPD (0.17 versus 0.08, = 0.018) than those in the non-COVID-19 group after COVID-19. Multivariate analysis revealed that COVID-19 infection is an independent risk factor for increased AECOPD incidence (adjusted odds ratio: 1.74; 95% confidence interval [CI]: 1.07-2.83, = 0.024). Within the COVID-19 group, the inpatient subgroup exhibited a higher prevalence of heart failure comorbidity (20% versus 2.8%, = 0.035) and lower forced vital capacity than the outpatient subgroup (2.03 ± 0.60 L versus 2.56 ± 0.72 L, = 0.016).

CONCLUSION

Age is a significant risk factor for COVID-19 infection among patients with COPD. After COVID-19, these patients exhibit an increased frequency of severe exacerbations and a high risk of mortality. Notably, the susceptibility to severe exacerbations persists regardless of whether the patients receive inpatient or outpatient care.

摘要

背景

研究表明,慢性阻塞性肺疾病(COPD)是2019冠状病毒病(COVID-19)患者的不良预后因素。由于研究有限,COPD患者中COVID-19的长期并发症仍知之甚少。

方法

这项回顾性研究纳入了2020年1月1日至2022年12月31日期间在一家医疗中心接受定期随访的COPD患者。患者被分为COVID-19组和非COVID-19组。进行比较分析以评估两组之间的临床人口统计学、特征、慢性阻塞性肺疾病急性加重(AECOPD)和生存率。基于COVID-19组内的住院和门诊状态进行亚组分析。

结果

在696例COPD患者中,86例(12.4%)被纳入COVID-19组,610例(87.6%)被纳入非COVID-19组。COVID-19组患者的年龄显著更大(年龄:75.0±8.8岁对72.0±9.0岁,P = 0.004),死亡率更高(4.6%对0%,P<0.001),且COVID-19后AECOPD的年度发作次数增加(0.17对0.08,P = 0.018)。多因素分析显示,COVID-19感染是AECOPD发病率增加的独立危险因素(调整后的优势比:1.74;95%置信区间[CI]:1.07 - 2.83,P = 0.024)。在COVID-19组内,住院亚组的心力衰竭合并症患病率更高(20%对2.8%,P = 0.035),且用力肺活量低于门诊亚组(2.03±0.60 L对2.56±0.72 L,P = 0.016)。

结论

年龄是COPD患者感染COVID-19的重要危险因素。COVID-19后,这些患者的严重加重发作频率增加且死亡风险高。值得注意的是,无论患者接受住院治疗还是门诊治疗,严重加重的易感性都持续存在。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc1c/12282603/54a2a0e84d2d/COPD-20-2539-g0001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验